---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-073324"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:19:27.238068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports FY2023 net loss $76.4M, cash $360.4M; AURORA topline data expected March/April 2024

## Summary
- Cash and cash equivalents $360.4M at Dec 31, 2023, providing runway well into 2026.
- Net loss of $76.4M for FY2023 vs $46.8M in 2022, driven by higher R&D costs ($69.3M vs $33.4M).
- Topline results from AURORA phase 2 study of bitopertin in EPP expected March/April 2024.
- Updated phase 1b/2 data for DISC-0974 in anemia of myelofibrosis expected 1H 2024.
- Appointed Jean Franchi as CFO, Pamela Stephenson as CCO, promoted Jonathan Yu to COO.

## SEC filing metadata
- accession: 0001193125-24-073324
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/0001193125-24-073324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/d795577d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-073324
- JSON: https://secwatch.observer/filing/0001193125-24-073324.json
- Plain text: https://secwatch.observer/filing/0001193125-24-073324.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $76.4 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: Net loss was $76.4 million
  - Result: reported results
  source text: Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/0001193125-24-073324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.